| PATENT NUMBER | This data is not available for free |
| PATENT GRANT DATE | 31.12.02 |
| PATENT TITLE |
Methods for recombinant peptide production |
| PATENT ABSTRACT | The present invention provides improved methods for the production of recombinant peptides from bacterial cells |
| PATENT INVENTORS | This data is not available for free |
| PATENT ASSIGNEE | This data is not available for free |
| PATENT FILE DATE | January 12, 2001 |
| PATENT REFERENCES CITED |
Szoka et al, "A general method for retrieving the components of a genetically engineered fusion protein", DNA 5(1):11-20.* Laemmli et al, "Cleavage of structural proteins during the assembly of the head of bacteriophage T4", Nature 227:680-685.* Powell, ACS Symp Ser. 567:100-17 Abstract Only.* Bongers, J., et al., "Enzymatic semisynthesis of a superpotent analog of human growth hormone-releasing factor", J. Med. Chem. 35: 3934-3941 (1992). Bongers, J., et al., "Semisynthesis of human growth hormone-releasing factor by trypsin catalyzed coupling of leucine amide to a C-terminal acid precursor", Int. J. Peptide Protein Res. 40:268-273 (1992). Calloway, Lai, et al., "Modification of the C terminus of cecropin is essential for broad-spectrum antimicrobial activity", Antimicrob. Agents & Chemo., 37:1614 (1993). Canova-Davis, E., et al., "Chemical heterogeneity as a result of hydroxylamine cleavage of a fusion protein of human insulin-like growth factor I", Biochem. J. 285: 207-213 (1992). Cunningham, B.C., et al., "Production of an atrial natriuretic peptide variant that is specific for type A receptor", EMBO J. 13: 2508-2515 (1994). Dykes, et al., "Expression of atrial natriuretic factor as a cleavable fusion protein with chloramphenicol acetyltransferase in Escherichia coli", Eur. J. Biochem. 174, 411-416 (1988). Forsberg, et al., "Comparison of two chemical cleavage methods for preparation of a truncated form of recombinant human insulin-like growth factor I from a secreted fusion protein", Biofactors 2, 105-112 (1989). Forsberg, et al., "An evaluation of different enzymatic cleavage methods for recombinant fusion proteins, applied on Des(1-3)insulin-like growth factor I", I.J. Protein Chem. 11, 201-211 (1992). Gazzano-Santoro, et al., "High-Affinity Binding of the Bactericidal/Permeability-Increasing Protein and a Recombinant Amino-Terminal Fragment to the Lipid A Region of Lipopolysaccharide", Infect. Immun. 60, 4754-4761 (1992). Gram, et al., "A novel approach for high level production of a recombinant human parathyroid hormone fragment in Escherichia coli", Bio/Technology 12, 1017-1023 (1994). Gray, et al., "Cloning of the cDNA of a human neutrophil bactericidal protein", J. Biol. Chem., 264, 9505 (1989). Han, et al., "Current developments in chemical cleavage of proteins", Int. J. Biochem 15: 875-884 (1983). Harrison, S.J., et al., "Purification and characterization of a plant antimicrobial peptide expressed in Escherichia coli", Protein Expr. Purif. 15: 171-177 (1999). Haught, et al., "Recombinant Production and Purification of Novel Antisense Antimicrobial Peptide in Escherichia coli", Biotechnol. Bioengineer., 57, 55-61 (1998). Huston, J., et al., "Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli", Proc. Nat'l. Acad. Sci. USA 85: 5879-5883 (1988). Kelley, "Therapeutic Peptides: The Devil is in the Details", Bio/Technology 14, 28-31 (1996). Kempe, et al., "Multiple-copy genes: production and modification of monomeric peptides from large multimeric fusion proteins", Gene, 39, 239-245 (1985). Knott, et al., "The isolation and characterisation of human atrial natriuretic factor produced as a fusion protein in Escherichia coli", Eur. J. Biochem. 174, 405-410 (1998). Kuliopulos, et al., "Production, Purification, and Clevage of Tandem Repeats of Recombinant Peptides", J. Am. Chem. Soc., 116:4599 (1994). LaVallie, et al., "A Thioredoxin Gene Fusion Expression System that Circumvents Inclusion Body Formation in the E. coli Cytoplasm", Bio/Technology 11, 187-193 (1993). Lee, J. et al., "Acidic peptide-mediated expression of the antimicrobial peptide buforin II as tandem repeats in Escherichia coli" Protein Expr. Purif. 12:53-60 (1998). Lennick, et al., "High-level expression of .A-inverted.-human atrial natriuretic peptide from multiple joined genes in Escherichia coli", Gene, 61, 103 (1987). Little, et al., "Functional domains of recombinant bactericidal/permeability increasing protein", J. Biol. Chem. 269: 1865-1872 (1994). Marcus, "Preferential cleavage at aspartyl-prolyl peptide bonds in dulite acide", Int. J. Peptide Protein Res., 25, 542-546 (1985). Merkler, D., "C-terminal amidated peptides: production by the in vitro enzymatic amidation of glycine-extended peptides and the importance of the amide to bioactivity", Enzyme Microb. Technol. 16: 450-456 (1994). Moks, et al., "Large-scale affinity purification of human insulin-like growth factor I from culture medium of Escherichia coli", Bio/Technology 5, 379-382 (1987). Ozkaynak, E. et al., "OP-1 cDNA encodes an osteogenic protein in the TGF-beta family", EMBO J. 9:2085-2093 (1990). Park, et al., "High level expression of the angiotensin-converting-enzyme-inhibiting peptide, YG-1, as tandem multimers in Escherichia coli", Appl. Microbiol. Biotechnol. 50:71-76 (1998). Piers, et al., "Recombinant DNA procedures for producing small antimicrobial cationic peptides in bacteria", Gene 134, 7-13 (1993). Pilon, et al., "Ubiquitin Fusion Technology: Bioprocessing of Peptides", Biotechnol. Prog., 13, 374-379 (1997). Poulsen, K., et al., "An active derivative of rabbit antibody light chain composed of the constant and the variable domains held together only by a native disulfide bond", Proc. Nat'l. Acad. Sci. USA 69: 2495-2499 (1972). Poulsen, K., et al., "Specific cleavage between variable and constant domains of rabbit antibody light chains by dilute acid hydrolysis", Biochemistry 11: 4974-4977 (1972). Ray, et al., "Production of recombinant salmon calcitonin by in vitro amidation of an Escherichia coli produced precursor peptide", Bio/Technology, 11, 64-70 (1993). Schellenberger, et al., "Peptide production by a combination of gene expression, chemical synthesis, and protease-catalyzed conversion", Int. J. Peptide Protein Res., 41, 326 (1993). Shen, "Multiple joined genes prevent product degradation in Escherichia coli", Proc. Nat'l. Acad. Sci. (USA) 281, 4627 (1984). Tsao, et al., "A versitile plasmid expression vector for the production of biotinylated proteins by site-specific, enzymatic modification in Escherichia coli", Gene 169, 59-64 (1996). Uhlen, et al. "Gene fusion vectors based on the gene for staphylococcal protein A", Gene 23, 369:378 (1983). Zhong, L., et al., "Design and synthesis of amphipathic antimicrobial peptides", Int. J. Peptide Protein Res. 45: 337-347 (1995). |
| PATENT PARENT CASE TEXT | This data is not available for free |
| PATENT CLAIMS |
What is claimed is: 1. In a method for obtaining a peptide from bacterial cells after expression inside the cells of a fusion protein, wherein the fusion protein comprises the peptide, a carrier protein and an acid-cleavable site between the peptide and the carrier protein, the improvement comprising: treating the bacterial cells with acid under conditions sufficient in a single step to disrupt or lyse the cells and release the peptide from the fusion protein, wherein the bacterial cells are in cell culture media for the acid treatment. 2. The method of claim 1 with the additional step of obtaining the released peptide separated from the disrupted or lysed cells. 3. The method of claim 2 wherein the released peptide is separated from the disrupted or lysed cells by a separation device. 4. The method of claim 3 wherein the separation device is a centrifugation device. 5. The method of claim 3 wherein the separation device is a filtration device. 6. The method of claim 1 wherein the acid-cleavable site in the fusion protein is Asp-Pro. 7. The method of claim 1 wherein the carrier protein is expressed as an insoluble protein inside the bacterial cells. 8. The method of claim 7 wherein the carrier protein is the D subunit of human osteogenic protein. 9. The method of claim 1 wherein the bacterial cells have been separated from cell culture media for the acid treatment. 10. The method of claim 1 wherein the bacterial cells are in cell culture media in a fermentation vessel for the acid treatment. 11. In a method for obtaining a peptide from bacterial cells after expression inside the cells of a fusion protein, wherein the fusion protein comprises the peptide, a carrier protein and an acid-cleavable site between the peptide and the carrier protein, the improvement comprising: (a) treating the bacterial cells with acid under conditions sufficient to disrupt or lyse the cells and release the peptide from the fusion protein, wherein the bacterial cells are in cell culture media for the acid treatment, (b) separating soluble material from insoluble material after step (a), and (c) recovering the released peptide in the soluble material after step (b). 12. The method of claim 11 wherein the soluble material is separated from the insoluble material by a separation device. 13. The method of claim 12 wherein the separation device is a centrifugation device. 14. The method of claim 12 wherein the separation device is a filtration device. 15. The method of claim 11 wherein the acid-cleavable site in the fusion protein is Asp-Pro. 16. The method of claim 11 wherein the carrier protein is expressed as an insoluble protein inside the bacterial cells. 17. The method of claim 16 wherein the carrier protein is the D subunit of human osteogenic protein. 18. The method of claim 11 wherein the bacterial cells have been separated from cell culture media for the acid treatment. 19. The method of claim 11 wherein the bacterial cells are in cell culture media in a fermentation vessel for the acid treatment. -------------------------------------------------------------------------------- |
| PATENT DESCRIPTION |
The present invention relates generally to improved methods for the production of recombinant peptides from bacterial cells. BACKGROUND OF THE INVENTION Although bioactive peptides can be produced chemically by a variety of synthesis strategies, recombinant production of peptides, including those in the 50 amino acid size range, offers the potential for large scale production at reasonable cost. However, expression of very short polypeptide chains can sometimes be problematic in microbial systems, including in bacterial cells such as Escherichia coli. This is true even when the peptide sequence is expressed as part of a fusion protein. As part of a fusion protein, peptides may be directed to specific cellular compartments, i.e. cytoplasm, periplasm, or media, with the goal of achieving high expression yield and avoiding cellular degradative processes. Preparation of a peptide from a fusion protein in pure form requires that the peptide be released and recovered from the fusion protein by some mechanism and then obtained by isolation or purification. Methods for cleaving fusion proteins have been identified. Each method recognizes a chemical or enzymatic cleavage site that links the carrier protein to the desired protein or peptide [Forsberg et al., I. J. Protein Chem. 11, 201-211, (1992)]. Chemical cleavage reagents in general recognize single or paired amino acid residues which may occur at multiple sites along the primary sequence, and therefore may be of limited utility for release of large peptides or protein domains which contain multiple internal recognition sites. However, recognition sites for chemical cleavage can be useful at the junction of short peptides and carrier proteins. Chemical cleavage reagents include cyanogen bromide, which cleaves at methionine residues [Piers et al., Gene, 134, 7, (1993)], N-chloro succinimide [Forsberg et al., Biofactors 2, 105-112, (1989)] or BNPS-skatole [Knott et al., Eur. J. Biochem. 174, 405-410, (1988); Dykes et al., Eur. J. Biochem. 174, 411-416, (1988)] which cleaves at tryptophan residues, dilute acid which cleaves aspartyl-prolyl bonds [Gram et al., Bio/Technology 12, 1017-1023, (1994); Marcus, Int. J. Peptide Protein Res., 25, 542-546, (1985)], and hydroxylamine which cleaves asparagine-glycine bonds at pH 9.0 [Moks et al., Bio/Technology 5, 379-382, (1987)]. Of interest is U.S. Pat. No. 5,851,802 which describes a series of recombinant peptide expression vectors that encode peptide sequences derived from bactericidal/permeability-increasing protein (BPI) linked via amino acid cleavage site sequences as fusions to carrier protein sequences. In some fusion protein constructs, an acid labile aspartyl-prolyl bond was positioned at the junction between the peptide and carrier protein sequences. BPI-derived peptides were released from the fusion proteins by dilute acid treatment of isolated inclusion bodies without prior solubilization of the inclusion bodies. The released peptides were soluble in the aqueous acidic environment. In addition, BPI-derived peptides were obtained from fusion proteins under conditions where the fusion proteins were secreted into the culture medium. Those secreted fusion proteins were then purified and treated with dilute acid to release the peptide. Of additional interest are the disclosures of the following references which relate to recombinant fusion proteins and peptides. Shen, Proc. Nat'l. Acad. Sci. (USA), 281, 4627 (1984) describes bacterial expression as insoluble inclusion bodies of a fusion protein encoding pro-insulin and .beta.-galactosidase; the inclusion bodies were first isolated and then solubilized with formic acid prior to cleavage with cyanogen bromide. Kempe et al., Gene, 39, 239 (1985) describes expression as insoluble inclusion bodies in E. coli of a fusion protein encoding multiple units of neuropeptide substance P and .beta.-galactosidase; the inclusion bodies were first isolated and then solubilized with formic acid prior to cleavage with cyanogen bromide. Lennick et al., Gene, 61, 103 (1987) describes expression as insoluble inclusion bodies in E. coli of a fusion protein encoding multiple units (8) of .alpha.-human atrial natriuretic peptide; the inclusion bodies were first isolated and then solubilized with urea prior to endoproteinase cleavage. Dykes et al., Eur. J. Biochem., 174, 411 (1988) describes soluble intracellular expression in E. coli of a fusion protein encoding .alpha.-human atrial natriuretic peptide and chloramphenicol acetyltransferase; the fusion protein was proteolytically cleaved or chemically cleaved with 2-(2-nitrophenylsulphenyl)-E-methyl-3'-bromoindolenine to release peptide. Ray et al., Bio/Technology, 11, 64 (1993) describes soluble intracellular expression in E. coli of a fusion protein encoding salmon calcitonin and glutathione-S-transferase; the fusion protein was cleaved with cyanogen bromide. Schellenberger et al., Int. J. Peptide Protein Res., 41, 326 (1993) describes expression as insoluble inclusion bodies of a fusion protein encoding a substance P peptide (11a.a.) and .beta.-galactosidase; the inclusion bodies were first isolated and then treated with chymotrypsin to cleave the fusion protein. Hancock et al., W094/04688 (PCT/CA93/00342) and Piers et al. (Hancock), Gene, 134, 7 (1993) describe (a) expression as insoluble inclusion bodies in E. coli of a fusion protein encoding a defensin peptide designated human neutrophil peptide 1 (HNP-1) or a hybrid cecropin/mellitin (CEME) peptide and glutathione-5-transferase (GST); the inclusion bodies were first isolated and then: (i) extracted with 3% octyl-polyoxyethylene prior to urea solubilization and prior to factor X.sub.a protease for HNP1-GST fusion protein or (ii) solubilized with formic acid prior to cyanogen bromide cleavage for CEME-GST fusion protein; (b) expression in the extracellular supernatant of S. aureus of a fusion protein encoding CEME peptide and protein A; (c) proteolytic degradation of certain fusion proteins with some fusion protein purified; and (d) proteolytic degradation of other fusion proteins and inability to recover and purify the fusion protein. Lai et al., U.S. Pat. No. 5,206,154 and Callaway, Lai et al. Antimicrob. Agents & Chemo., 37:1614 (1993) describe expression as insoluble inclusion bodies of a fusion protein encoding a cecropin peptide and the protein encoded by the 5'-end of the L-ribulokinase gene; the inclusion bodies were first isolated and then solubilized with formic acid prior to cleavage with cyanogen bromide. Gramm et al., Bio/Technology, 12:1017 (1994) describes expression as insoluble inclusion bodies in E. coli of a fusion protein encoding a human parathyroid hormone peptide and a bacteriophage T4-encoded gp55 protein; the inclusion bodies were first isolated (6% wt/vol.) and then were treated with acid to hydrolyze the Asp-Pro cleavage site. Kuliopulos et al., J. Am. Chem. Soc., 116:4599 (1994) describes expression as insoluble inclusion bodies in E. coli of a fusion protein encoding multiple units of a yeast .alpha.-mating type peptide and a bacterial ketosteroid isomerase protein; the inclusion bodies were first isolated and then solubilized with guanidine prior to cyanogen bromide cleavage. Pilon et al., Biotechnol. Prog., 13, 374-379 (1997) describe soluble intracellular expression in E. coli of a fusion protein encoding a peptide and ubiquitin; the fusion protein was cleaved with a ubiquitin specific protease, UCH-L3. Haught et al., Biotechnol. Bioengineer., 57, 55-61 (1998) describe expression as insoluble inclusion bodies in E. coli of a fusion protein encoding an antimicrobial peptide designated P2 and bovine prochymosin; the inclusion bodies were first isolated and then solubilized with formic acid prior to cleavage with cyanogen bromide. The above-references indicate that production of small peptides from bacteria has been problematic for a variety of reasons. Proteolysis of some peptides has been particularly problematic, even where the peptide is made as a part of a larger fusion protein. Such fusion proteins comprising a carrier protein/peptide may not be expressed by bacterial host cells or may be expressed but cleaved by bacterial proteases. In particular, difficulties in expressing cationic antimicrobial peptides in bacteria have been described by Hancock et al. WO94/04688 (PCT/CA93/00342) referenced above, due in their view to the susceptibility of such polycationic peptides to bacterial protease degradation. The production of peptide for preclinical and clinical evaluation often requires multigram quantities [Kelley, Bio/Technology 14, 28-31 (1996)]. If production of recombinant peptides can be achieved at this large scale, such production can potentially be economical. However, downstream processing steps for the production of peptides and proteins from bacteria can often contribute a significant fraction of total production cost. Initial recovery of peptide from bacterial inclusion bodies of fusion proteins, for example, generally requires multiple distinct processing steps, including the following four steps: (1) cell disruption/lysis, (2) isolation of inclusion bodies from the disrupted/lysed cells, (3) solubilization of the isolated inclusion bodies in denaturant or detergent to obtain solubilized fusion protein, and (4) fusion protein cleavage and separation of peptide and carrier protein. It is desirable that aspects of the recombinant production process be improved and/or optimized in order to make large-scale production of peptides by recombinant means more economically viable. There continues to exist a need in the art for improved methods for recombinant production of peptides from bacterial cells, particularly for simpler methods that do not require a multiplicity of steps, including, for example, the step of isolation or purification of peptide fusion proteins or the step of isolation or purification of inclusion bodies comprising the fusion proteins in order to obtain the recombinant peptide. SUMMARY OF THE INVENTION The present invention provides improved methods for the production of recombinant peptides from bacterial cells. The improved methods preclude the need for the isolation and solubilization of inclusion bodies or the isolation and purification of peptide fusion proteins. The improved methods accomplish cell disruption/lysis and release of peptide from bacterial cells or bacterial cell cultures in a single step. Fusion proteins useful in methods of the invention comprise at least one peptide sequence, a carrier protein sequence, and at least one acid-sensitive amino acid cleavage site sequence located between the peptide sequence and the carrier protein sequence. The invention provides improved methods for the microbial production of peptides from such fusion proteins expressed intracellularly in bacterial cells. The recombinant peptides recovered according to the invention are released by acid cleavage at the acid-sensitive cleavage site(s) in the fusion protein. Recombinant peptides are thus efficiently and economically produced according to the invention. The invention thus provides an improved method for obtaining a peptide from bacterial cells after expression inside the cells of a fusion protein, wherein the fusion protein comprises the peptide, a carrier protein and an acid-cleavable site between the peptide and the carrier protein, with the improvement comprising treating the bacterial cells with acid under conditions sufficient in a single step to disrupt or lyse the cells and release the peptide from the fusion protein. An improved method may include the additional step of obtaining the released peptide separated from the disrupted or lysed cells. According to the invention, the released peptide may be separated from the disrupted or lysed cells by a separation device, such as a centrifugation device or a filtration device. The invention also provides an improved method for obtaining a peptide from bacterial cells after expression inside the cells of a fusion protein, wherein the fusion protein comprises the peptide, a carrier protein and an acid-cleavable site between the peptide and the carrier protein with the improvement comprising the following steps: (a) treating the bacterial cells with acid under conditions sufficient to disrupt or lyse the cells and release the peptide from the fusion protein; (b) separating soluble material from insoluble material after step (a); and (c) recovering the released peptide in the soluble material after step (b). According to the invention, the soluble material may be separated from the insoluble material by a separation device, such as a centrifugation device or a filtration device. Improved methods of the invention may be employed where the bacterial cells are in cell culture media for the acid treatment, or where the bacterial cells have been separated from cell culture media for the acid treatment, or where the bacterial cells are in cell culture media in a fermentation vessel for the acid treatment. According to methods of the invention, preferred acid-cleavable sites in the fusion protein include an Asp-Pro cleavage site. Preferably, the carrier protein is expressed as an insoluble protein inside the bacterial cells. Improved methods of the invention for recombinant microbial production of peptides from fusion proteins are based on the surprising discovery that bacterial cell disruption/lysis and peptide release may be accomplished simultaneously in a single step. According to the invention, no process step is required for the isolation from the cells of inclusion bodies and solubilization of such inclusion bodies prior to peptide release and recovery. Similarly, no process step is required for the purification of the fusion proteins expressed in large amounts intracellularly as soluble or insoluble proteins in bacterial host cells prior to peptide release and recovery. Remarkably, peptides efficiently produced as components of fusion proteins by the bacterial host cells are efficiently cleaved and released from the fusion proteins by a single step of cell disruption/lysis and peptide release. It is particularly surprising that peptides according to the invention effectively made in E. coli are released in soluble form in this single step of cell disruption/lysis and peptide cleavage and are easily recovered from insoluble cell material. By way of example, recombinant BPI-derived peptides having one or more of the biological activities of BPI (e.g., LPS binding, LPS neutralization, heparin binding, heparin neutralization, antimicrobial activity) have been produced and recovered according to the methods of invention. Thus, the invention provides improved methods of bacterial cell production of functional recombinant peptides. |
| PATENT EXAMPLES | This data is not available for free |
| PATENT PHOTOCOPY | Available on request |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |